Invst LLC acquired a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 2,647 shares of the exchange traded fund’s stock, valued at approximately $246,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Avoro Capital Advisors LLC purchased a new stake in SPDR S&P Biotech ETF during the fourth quarter worth approximately $396,844,000. Affinity Asset Advisors LLC lifted its stake in SPDR S&P Biotech ETF by 105.4% during the second quarter. Affinity Asset Advisors LLC now owns 37,550 shares of the exchange traded fund’s stock worth $3,481,000 after purchasing an additional 737,550 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in SPDR S&P Biotech ETF by 30.3% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,136,000 shares of the exchange traded fund’s stock worth $297,575,000 after purchasing an additional 730,000 shares during the last quarter. Mirae Asset Securities USA Inc. purchased a new stake in SPDR S&P Biotech ETF during the second quarter worth approximately $55,626,000. Finally, Jane Street Group LLC lifted its stake in SPDR S&P Biotech ETF by 68.7% during the first quarter. Jane Street Group LLC now owns 961,082 shares of the exchange traded fund’s stock worth $91,197,000 after purchasing an additional 391,333 shares during the last quarter.
SPDR S&P Biotech ETF Stock Up 0.4 %
XBI stock opened at $98.80 on Tuesday. The business has a 50 day moving average price of $98.94 and a 200 day moving average price of $93.97. The stock has a market cap of $7.53 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a fifty-two week low of $63.80 and a fifty-two week high of $103.52.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- What is Put Option Volume?
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- The 3 Best Blue-Chip Stocks to Buy Now
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Find and Profitably Trade Stocks at 52-Week Lows
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.